Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CYAD

Celyad (CYAD) Stock Price, News & Analysis

Celyad logo

About Celyad Stock (NASDAQ:CYAD)

Advanced Chart

Key Stats

Today's Range
$0.40
$0.65
50-Day Range
$0.59
$0.85
52-Week Range
$0.46
$3.07
Volume
3,009 shs
Average Volume
N/A
Market Capitalization
$15.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CYAD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celyad and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CYAD Stock News Headlines

Celyad Oncology annonce la cessation des activités R&D
“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
Celyad Oncology Announces Strategic Review
See More Headlines

CYAD Stock Analysis - Frequently Asked Questions

Celyad (CYAD) raised $99 million in an initial public offering (IPO) on Friday, June 19th 2015. The company issued 1,400,000 shares at $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Celyad investors own include Galapagos (GLPG), Cellectis (CLLS), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), bluebird bio (BLUE), Bristol Myers Squibb (BMY) and

Company Calendar

Today
8/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
N/A
Current Symbol
NASDAQ:CYAD
CIK
1637890
Employees
95
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
1.49
Current Ratio
2.29
Quick Ratio
2.14

Sales & Book Value

Annual Sales
$200 thousand
Price / Sales
79.56
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
30.00

Miscellaneous

Outstanding Shares
26,520,000
Free Float
26,276,000
Market Cap
$15.91 million
Optionable
Not Optionable
Beta
N/A

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CYAD) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners